Sana Biotechnology, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
SANA$2.43-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development | $33,930 | $30,106 | $93,378 | $97,056 |
| Research and development related success payments and contingent consideration | (63,379) | 3,124 | (31,033) | 15,343 |
| General and administrative | 10,943 | 10,285 | 33,183 | 32,110 |
| Impairment of long-lived assets | - | - | - | 44,611 |
| Total operating expenses | (18,506) | 43,515 | 95,528 | 189,120 |
| Income (loss) from operations | 18,506 | (43,515) | (95,528) | (189,120) |
| Interest income, net | 1,219 | 1,003 | 3,299 | 2,572 |
| Other income, net | 676 | 360 | 1,785 | 1,207 |
| Net income (loss) | $20,401 | $(42,152) | $(90,444) | $(185,341) |
| Net income (loss) per common share – basic | $0.07 | $(0.16) | $(0.31) | $(0.75) |
| Weighted-average number of common shares – basic | 307,002 | 260,494 | 293,286 | 245,580 |
| Net income (loss) per common share – diluted | $0.07 | $(0.16) | $(0.31) | $(0.75) |
| Weighted-average number of common shares – diluted | 308,790 | 260,494 | 293,286 | 245,580 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.